Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir

NCT05423834 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT05423834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05423834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir
Lead sponsor
Chinese University of Hong Kong
Phase
Observational
Overall status
Active, not recruiting
Start date
September 1, 2022
Completion date
December 31, 2026
Enrollment
1,800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b